ABSTRACT The Ministry of Health (MOH) has updated the Clinical Practice Guidelines on Lipids to provide doctors and patients in Singapore with evidence-based treatment for lipids. This article reproduces the introduction and executive summary (with recommendations from the guidelines) from the MOH Clinical Practice Guidelines on Lipids, for the information of SMJ readers. Chapters and page numbers mentioned in the reproduced extract refer to the full text of the guidelines, which are available from the Ministry of Health website:
INTRODUCTION
Cardiovascular disease, especially coronary artery disease (CAD), is a very important health problem in Singapore today. CAD is second only to cancer as a leading cause of mortality in this country. Dyslipidemia is one of the most important modifiable risk factors for CAD. Many studies have demonstrated the efficacy of treating dyslipidemia in the prevention of CAD.
Objectives and scope
The main aim of these guidelines is to assist physicians and other healthcare professionals in clinical decision making by providing well-balanced information on the management of patients with dyslipidemia, without restricting the physician's individual clinical judgement.
Target group
These guidelines are developed for all health care professionals, in particular, primary care physicians who are involved in the care of patients with dyslipidemia.
Guideline development
The workgroup, comprising cardiologists, endocrinologists, lipid specialists, public health specialists and family physicians, was appointed by the Ministry of Health (MOH) to develop these guidelines.
What's new in the revised guidelines
This revision of the guideline incorporates data from several recent randomised controlled trials that have been published since 2006. In doing so, the committee has tried to simplify the recommendations, wherever possible. The key revisions are in the following chapters: 1.
The chapter on risk assessment (page 24) has been revised to: (a) Do away with the previous approach of counting risk factors as part of the algorithm for risk stratification.
In its place is a two-step process that stratifies patients into one of four levels of risk of CAD (very high risk, high risk, intermediate risk and low risk). (b) Include clear guidelines for the diagnosis of familial hypercholesterolemia and recognise that patients with familial hypercholesterolemia are at very high risk of CAD and, therefore, should be treated aggressively. (c) Introduce chronic kidney disease as one of the risk factors to consider when stratifying patients by risk of future CAD. (d) Recognise that patients with diabetes mellitus may not necessarily experience the same risk as patients with established CAD. As such, patients with diabetes mellitus can be stratified into two levels of risk (very high or high risk) based on the presence or absence of chronic kidney disease. (e) Retain treat to target levels of low-density lipoprotein (LDL) cholesterol based on the risk of CAD in individual patients. However, there is also the option for physicians to increase the dose of statins to those used in randomised controlled trials, even when the LDL cholesterol targets have been achieved. 2.
The chapter on lifestyle changes (page 36) has been extensively revised to focus on areas that are supported by the strongest evidence, including some food-based dietary recommendations (in addition to macronutrients) to help physicians support the dietary changes necessary for patients. 3. The chapter on drug therapy (page 40) has been revised to:
( The decision to start a statin should also take into account the life expectancy and the quality of life of these patients.
Review of guidelines
Evidence-based clinical practice guidelines (CPGs) are only as current as the evidence that supports them. Users must keep in mind that new evidence could supersede recommendations in these guidelines. The workgroup advises that these guidelines be scheduled for review five years after publication, or if new evidence appears that requires substantive changes to the recommendations. This CPG refers to the CPG on Screening for Cardiovascular Disease and Risk Factors (MOH CPG 1/2011). As such, revision of this CPG could be undertaken in the event of a revision to MOH CPG 1/2011. 
Classification and screening for dyslipidemia

Risk assessment of CAD in dyslipidemia
A basic principle in the prevention of CAD is that the intensity of risk reduction therapy should be adjusted to a person's risk of developing future coronary events. The steps taken for risk stratification are illustrated in Fig. 1 . First, very high risk and high risk patients can be identified based on whether they have existing CAD, atherosclerotic cerebrovascular disease, aortic aneurysm, peripheral arterial disease, diabetes mellitus, chronic kidney disease, or familial hypercholesterolemia. If the patient is not in the very high risk or high risk strata, his/her ten-year CAD risk can be estimated using Tables A-1 to A-4 (CPG pg. 21-24).
Target lipid levels
While it was noted that randomised controlled trials used fixed doses of statins, physicians in Singapore involved in treating patients at risk of CAD with lipid lowering therapy were of the view that there was sufficient evidence for a causal link between LDL cholesterol and the risk of CAD, such that a strategy to treat patients to achieve target lipid levels (i.e. treat to target strategy) remains relevant today. Table 3 shows the recommended LDL cholesterol target levels in the four risk group categories. It is also notable that in 2013, the American College of Cardiology (ACC) and the American Heart Association (AHA) released a guideline on the treatment of blood cholesterol in which treatment initiation and statin dose were driven primarily by CAD risk status and not by LDL cholesterol level. The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults recommended: (a) high intensity statin therapy, e.g. atorvastatin 40-80 mg, or its equivalent, in very high risk patients with clinical atherosclerotic cardiovascular disease; and (b) moderate intensity statin therapy, e.g. simvastatin 20-40 mg, or its equivalent, in high risk patients with diabetes mellitus without established chronic CAD or chronic kidney disease.
High intensity statin therapy is defined as the ability to lower LDL cholesterol by more than 50%. This is a property of the specific statin at the dose indicated.
The ACC/AHA recommendation is based on randomised controlled trials of lipid lowering for the prevention of CAD, which used fixed doses of statins, as opposed to treating patients to a specific target as many other guidelines recommended. However, this view is not universally accepted by physicians at this time. Other guidelines continue to recommend targets for treatment of dyslipidemia.
Physicians may consider increasing the statin therapy to the doses recommended in ACC/AHA guidelines, if tolerated, even after the LDL cholesterol goal is achieved on a lower dose of statin, especially if the patient is not on other lipid lowering therapy. However, when doing so, the physician and the patient must B 
Statins
Statins are very effective in lowering both TC and LDL cholesterol. The approximate equipotency of the different statins is as follows: 10 mg atorvastatin = 5 mg rosuvastatin = 20 mg simvastatin = 40 mg lovastatin/pravastatin = 80 mg fluvastatin. Some statins, including atorvastatin, simvastatin and lovastatin, are metabolised by the cytochrome P450 isoform 3A4. Drugs such as erythromycin, clarithromycin, azole antifungal agents and cyclosporine, which are also metabolised by the same enzyme pathway, may elevate the serum level of these statins when administered concomitantly, and therefore, may increase the risk of toxicity. Other statins such as pravastatin are not affected, as they are metabolised by other pathways. Omega 3 fish oils can lower TC (due to lowering of TG) but has no effect on LDL cholesterol and cardiovascular mortality. Thus, they should not be used as a substitute for statins.
Precautions in diabetes mellitus
Use of combination therapy with statins D
The decision to combine a statin and another lipid lowering agent must be individualised and should be initiated only when it is strongly indicated. When statin therapy fails to achieve LDL target on the maximum tolerated dose, consideration should be given to use either ezetimibe or resin as an add-on drug to achieve the LDL target level for the patient. (Table 6 ) and process indicators for review frequency (Table 7) are proposed for lipid management. However, measurement of attainment of these target levels should exclude those aged > 75 years. In the management of an individual patient, good clinical judgement, which takes into account other factors that may influence overall morbidity or mortality risk, should be exercised in every situation. As such, aiming for 100% attainment of these targets is inappropriate. Furthermore, measurements of attainment of these targets should exclude those aged > 75 years. Recommended best practice based on the clinical experience of the guideline development group.
